Clinical Trials at The University of Texas MD Anderson Cancer Center
As of June 2026, 141 paid clinical trials are recruiting at The University of Texas MD Anderson Cancer Center, located at 1515 HOLCOMBE BLVD UNIT 428, HOUSTON, TX 77030-4028, phone (713) 794-1464 in Houston, Texas. Active studies at this site cover conditions such as Breast Cancer, Advanced Solid Tumor and Acute Myeloid Leukemia. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
141 clinical trials at The University of Texas MD Anderson Cancer Center
·Clear filters·↓ Download CSVL19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
L19IL2/TNF in Patients With Basal Cell Carcinoma
L19IL2/L19TNF in Patients With Cutaneous Squamous Cell Carcinoma
A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Circulating Tumor DNA
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.
A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors
A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
Study of AUBE00 in Patients With Solid Tumors
Remotely Monitored, Mobile Health-supported, High Intensity Interval Training Before Hematopoietic Stem Cell Transplant
BOLSTER: Learning New Skills to Thrive
Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer
CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
A Study of HS-20110 in Participants With Advanced Solid Tumors
Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia
About research studies in Houston
Houston has approximately 3,144 recruiting research studies across a wide range of therapeutic areas. Texas hosts major cancer and cardiovascular research centers including MD Anderson Cancer Center, Baylor College of Medicine, UT Southwestern Medical Center, and the Texas Medical Center — the largest medical complex in the world.
Common conditions studied in Houston
- Breast Cancer (87 active studies). Breast cancer trials evaluate new hormone therapies, targeted drugs, and immunotherapy combinations aimed at improving survival and reducing recurrence.
- Advanced Solid Tumor (59 active studies). Recruiting Advanced Solid Tumor studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Acute Myeloid Leukemia (58 active studies). Leukemia trials evaluate targeted inhibitors, CAR-T cell therapies, and novel combinations for acute and chronic forms of the disease.
- Ovarian Cancer (53 active studies). Ovarian cancer research examines PARP inhibitors, maintenance therapies, and antibody-drug conjugates for recurrent and platinum-resistant disease.
- Colorectal Cancer (45 active studies). Colorectal cancer trials explore novel chemotherapy combinations, targeted agents, and immunotherapy for microsatellite-instability-high tumors.
- Prostate Cancer (45 active studies). Prostate cancer studies test next-generation hormone therapies, PARP inhibitors, and radioligand treatments for both localized and advanced disease.
Leading research sponsors in Houston
- M.D. Anderson Cancer Center
- The University of Texas Health Science Center, Houston
- Baylor College of Medicine
- AstraZeneca
- Eli Lilly and Company
Local regulations and guidelines
Clinical trials in Texas are governed by U.S. Food and Drug Administration (FDA) regulations, Office for Human Research Protections (OHRP) standards, and federal HIPAA privacy rules. Every study is reviewed by an Institutional Review Board (IRB) to protect participant safety and ensure informed consent. Trials run in Texas must also comply with the Texas Medical Privacy Act (TMPA), which extends federal HIPAA protections to a broader range of entities handling participant data.
Compensation & what to expect
- How payment typically works
- Compensation is most often provided through reloadable electronic study cards or direct deposit, paid out per completed visit rather than as a lump sum. Amounts vary by the time required, the number of visits, and the study's complexity — overnight stays and inpatient pharmacology studies generally pay more than short outpatient surveys. The exact amount is disclosed in writing during informed consent before any visit.
- Healthy volunteers
- Healthy participants aged 18 and older can earn compensation by joining vaccine, pharmacology, and biomarker studies in Houston. These trials check how a new drug or vaccine behaves in healthy bodies before later-phase testing. Many sites maintain a healthy-volunteer registry so you hear about new opportunities first.
- What's included beyond payment
- Most trials cover study-related medical care at no cost — physical exams, lab work, imaging, the investigational treatment itself, and follow-up visits with the research team. Insurance is not required to participate. Free check-ups and access to specialists are common reasons participants return for additional studies.
- Travel and time
- Many sponsors reimburse travel, parking, mileage, and lost wages for visit days. Long-running studies and trials that require frequent visits often raise stipends accordingly. Ask the study coordinator for the visit schedule and reimbursement policy before you commit.
- Asking about compensation
- Compensation is set per protocol and per site, so figures are not published in trial registries. The fastest way to confirm payment for a specific study is to contact the recruiting site listed on the study record. Coordinators are accustomed to this question and will quote the per-visit and total amounts up front.
How to find a clinical trial in Houston
Hipa.ai aggregates every recruiting study in Houston from ClinicalTrials.gov and refreshes the list daily. Use the filters above to narrow by condition, facility, age, phase, or healthy-volunteer eligibility, then click any study title to view full details — eligibility criteria, intervention, location, and sponsor contact information. To enroll, reach out to the central study contact listed on the study detail page; the research coordinator will walk you through the screening process.
Frequently asked questions
How many paid clinical trials are currently recruiting in Houston?
There are approximately 3,144 recruiting clinical trials in Houston, Texas listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Houston pay participants?
Most recruiting trials in Houston compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Houston?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Houston?
The most common conditions under active study in Houston include Breast Cancer (87), Advanced Solid Tumor (59), Acute Myeloid Leukemia (58), Ovarian Cancer (53), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Houston?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Houston on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Houston?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Houston?
Recruiting research sites in Houston include MD Anderson Cancer Center, M D Anderson Cancer Center, Baylor College of Medicine, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Houston right now?
The largest active categories in Houston are Cancer & tumors (1,268), Neurology & pain (148), Diabetes & metabolic (97). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of The University of Texas MD Anderson Cancer Center?
The University of Texas MD Anderson Cancer Center is located at 1515 HOLCOMBE BLVD UNIT 428, HOUSTON, TX 77030-4028. Use the Google Maps link in the intro above to get directions.
How do I contact The University of Texas MD Anderson Cancer Center?
You can reach The University of Texas MD Anderson Cancer Center by phone at (713) 794-1464. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.